Key Takeaways Pulse Biosciences shifts focus to nPulse AFib system after strong 150-patient European study results.PLSE's nsPFA tech showed 100% procedural success at 6 months and 96% sustained success at 12 months.Pulse Biosciences reallocates capital to support pivotal studies and future regulatory submissions.Pulse Biosciences (PLSE) recently announced a strategic shift aimed at accelerating the development and future commercialization of its nPulse Cardiac Catheter Ablation System. The initiative follow ...